Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) Age: adults and pediatric patients greater than 12 years |
Dose: Oral – 300 mg nirmatrelvir plus 100 mg ritonavir Frequency: twice daily Duration: 5 days Note: Initiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset. Hepatic impairment Mild or moderate (Child-Pugh Class A or B): No dosage adjustment required. |
|
Indication: Treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) Age: adults and pediatric patients greater than 12 years Condition: Severe hepatic impairment (Child-Pugh Class C) |
Dose: Oral Note: Not recommended; data are unavailable. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) Age: pediatric patients (aged greater than 12 years) Condition: testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and who are at high risk for progression to severe COVID-19, including hospitalization or death |
Dose: Oral – 300 mg nirmatrelvir plus 100 mg ritonavir Frequency: twice daily Duration: 5 days Note: by mouth (oral); Emergency use authorization issued; Initiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild (estimated Glomerular Filtration Rate greater than 60 to less than 90 mL/min) |
Dose: Tablet – 300 mg nirmatrelvir plus 100 mg ritonavir Note: No dosage adjustment required |
|
Condition: Renal impairment Moderate (estimated Glomerular Filtration Rate greater than 30 to less than 60 mL/min) |
Dose: Tablet – 150 mg nirmatrelvir plus 100 mg ritonavir Frequency: twice daily Duration: 5 days Note: Decrease to this dose |
Administration
- May take with or without food
- Take doses 12 hours apart
Side Effect
- Dysgeusia (6%)
- Diarrhea (3%)
- Hypertension (1%)
- Myalgia (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A substrates
|
May increase plasma concentrations
|
|
CYP3A inducers
|
May decrease nirmatrelvir and ritonavir plasma concentrations and reduce therapeutic effect
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.